Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C3YN
|
||||
| Former ID |
DIB016404
|
||||
| Drug Name |
Heparin low molecular weight
|
||||
| Synonyms |
Heparin low molecular weight, Watson Laboratories; Heparin transmucosal, TheraTech
|
||||
| Indication | Thrombosis [ICD9: 437.6, 453, 671.5, 671.9; ICD10:I80-I82] | Phase 3 | [1] | ||
| Company |
Watson Laboratories Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Antithrombin-III | Target Info | Modulator | [2] | |
| KEGG Pathway | Complement and coagulation cascades | ||||
| PANTHER Pathway | Blood coagulation | ||||
| Pathway Interaction Database | Glypican 1 network | ||||
| Reactome | Intrinsic Pathway of Fibrin Clot Formation | ||||
| Common Pathway of Fibrin Clot Formation | |||||
| WikiPathways | Complement and Coagulation Cascades | ||||
| Formation of Fibrin Clot (Clotting Cascade) | |||||
| References | |||||
| REF 1 | Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006 Jun;81(6):758-67. | ||||
| REF 2 | Effects of low molecular weight heparin on a severely antithrombin III-decreased disseminated intravascular coagulation model in rabbits. Thromb Res. 1995 Dec 1;80(5):391-8. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.